Doxorubicin and trabectedin for recurrent leiomyosarcoma – A case report
Uterine leiomyosarcoma (LMS) represents a rare yet highly aggressive tumor, comprising approximately 1% of uterine malignancies. First-line regimens involving doxorubicin or gemcitabine and docetaxel demonstrate modest response rates. Notably, the combination of doxorubicin plus trabectedin has emer...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2024-10-01
|
| Collection: | Gynecologic Oncology Reports |
| Sujets: | |
| Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S2352578924001760 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|